$CDIX

Cardiff Lexington Corp (CDIX): Entry into a Material Definitive Agreement

Cardiff Lexington Corp (CDIX) filed an SEC Form 8-K — Entry into a Material Definitive Agreement. EX-10.1 2 cardiff_ex1001.htm COMMON STOCK PURCHASE AGREEMENT, DATED JUNE 5, 2026 Exhibit 10.1 COMMON STOCK PURCHASE AGREEMENT This COMMON STOCK PURCHASE AGREEMENT is made and entered into as of June 5, 2026 (this “ Agreement ”), by and among Leonite Fund I, LP (the “ Investor ”),

Original reporting
Published Jun 11, 2026, 8:10 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Jun 11, 2026, 8:11 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
AlphAI market briefCorporate actions
Primary signal
$CDIX
Neutral
medium confidence
Mentioned
$CDIX
Relevance
6/10
AlphAI data visualization · based on SEC EDGAR 8-K
Decision brief

The 30-second read

$CDIXNeutralMed
01

Why it matters

The agreement creates an at-the-company’s-option pathway to issue common stock to the investor in tranches (fixed purchases) during an investment period, subject to conditions and a $0.20 minimum closing sale price for purchase direction.

02

Market read

This is a disclosed equity financing mechanism with a defined maximum commitment and a trading-price gate, which can drive dilution expectations and near-term trading volatility.

03

What to watch

Traders should monitor whether the $0.20 trading-price condition is met and how quickly fixed purchase notices are issued; actual dilution depends on executed settlements, not the maximum commitment.

Relevance 6/10Novelty 8/10Timing: Filed June 11, 2026 (8-K) with agreement dated June 5, 2026

Background

The 8-K reports entry into a Common Stock Purchase Agreement with Leonite Fund I, LP, including registration rights for resale of shares issued under the program.

Company-level read

Ticker impact

$CDIXNeutralMedium confidence
Context

CDIX entered a material definitive common stock purchase agreement allowing the company to sell up to $25M (expandable to $75M) to an investor.

Expected impact

Near-term volatility risk from dilution overhang; price sensitivity likely increases if the stock trades near the $0.20 threshold that governs purchases.

Evidence & confidence

This is a primary SEC 8-K disclosure of a financing structure, but the actual draw size/timing depends on future fixed purchase notices and satisfaction of conditions.

Market effects

Adds another microcap-style equity purchase agreement template, reinforcing dilution/financing risk premia in small-cap growth names.

Primarily US-listed microcap dynamics; limited cross-region spillover expected.

Low—this is company-specific financing mechanics with no stated global macro linkage.

Counterpoint

If the investor’s purchases are executed at favorable prices and the company uses proceeds efficiently, the agreement could reduce funding risk without immediate heavy dilution.

Key entities

  • Cardiff Lexington Corporation

    Nevada corporation issuing common stock under the purchase agreement.

  • Leonite Fund I, LP

    Investor purchasing shares under the fixed purchase mechanism.

  • Registration Rights Agreement

    Provides registration rights for resale of shares issued under the purchase agreement.

Related articles

$CDIXHighAI 8/10

Cardiff Lexington Corp (CDIX): Other Events

Cardiff Lexington Corp (CDIX) filed an SEC Form 8-K — Other Events. Exhibit 99.1 CARDIFF LEXINGTON CORPORATION ANNOUNCES LETTER OF INTENT FOR PROPOSED ACQUISITION OF LEADING MUSCULOSKELETAL HEALTHCARE PLATFORM Proposed Combination Would Significantly Expand Cardiff Lexington’s Musculoskeletal and Ancillary Healthcare Operations LEXINGTON, KY. — S

$CDIXMed

Cardiff Lexington Corporation: Cardiff Lexington Announces Second Quarter 2026 Financial Results

Cardiff Lexington Corporation (OTCQX:CDIX) filed its Form 10-Q for the quarter ended June 30, 2026. The company reported Q2 2026 revenue of $2.16M versus $2.79M in 2025, and a net loss of $2.48M. For six months, revenue fell to $4.38M and net loss was $5.57M. It cited working capital constraints and plans to evaluate debt restructuring and equity infusions.

$CLWMed

Clearwater Paper (CLW) Refinances Debt Through 2031. Does More Time Mean a Stronger Balance Sheet?

Clearwater Paper (CLW) refinanced its debt, securing a $275M term loan and $200M revolving facility, both maturing in 2031. The funds were used to redeem $275M of notes due 2028. The new facilities have a higher initial interest rate of 8.25% compared to the old 4.75% coupon. The company's first-half operating cash flow improved to $69.5M, aided by insurance recoveries and tax refunds.

$TTEMed

TotalEnergies (TTE) Eyes a Bigger $16 Billion Bet on Iraq: Could this Unlock More Growth?

TotalEnergies (TTE) and Iraq's government are discussing energy projects, potentially increasing investments from $12B to $16B. CEO Patrick Pouyanne aims to boost Iraq's oil production, leveraging existing infrastructure like the $10B Gas Growth Integrated Project (GGIP). Projects could support TTE's 3% production growth target by 2026, but details and geopolitical risks remain unclear.

$VKTXHighAI 8/10

What Viking Therapeutics Stock Means For Shareholders After Obesity Drug Data And $500 Million Raise

Viking Therapeutics (VKTX) reported positive obesity drug data for VK2735 and raised $500M, including $275M in common stock and $225M in convertible notes. The funds support R&D and Phase 3 trials but introduce future dilution risks. Analysts project $118.5M revenue and $12.9M earnings by 2029, with some forecasting higher figures. The company has no revenue and reported a $358.5M loss in 2025.